Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival.

Cerhan JR, Wang S, Maurer MJ, Ansell SM, Geyer SM, Cozen W, Morton LM, Davis S, Severson RK, Rothman N, Lynch CF, Wacholder S, Chanock SJ, Habermann TM, Hartge P.

Blood. 2007 Jun 15;109(12):5439-46.

2.

Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era.

Habermann TM, Wang SS, Maurer MJ, Morton LM, Lynch CF, Ansell SM, Hartge P, Severson RK, Rothman N, Davis S, Geyer SM, Cozen W, Chanock SJ, Cerhan JR.

Blood. 2008 Oct 1;112(7):2694-702. doi: 10.1182/blood-2007-09-111658.

3.

A comprehensive evaluation of the role of genetic variation in follicular lymphoma survival.

Baecklund F, Foo JN, Bracci P, Darabi H, Karlsson R, Hjalgrim H, Rosenquist R, Adami HO, Glimelius B, Melbye M, Conde L, Liu J, Humphreys K, Skibola CF, Smedby KE.

BMC Med Genet. 2014 Oct 8;15:113. doi: 10.1186/s12881-014-0113-6.

4.

Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma.

Charbonneau B, Maurer MJ, Fredericksen ZS, Zent CS, Link BK, Novak AJ, Ansell SM, Weiner GJ, Wang AH, Witzig TE, Dogan A, Slager SL, Habermann TM, Cerhan JR.

Am J Hematol. 2012 Sep;87(9):880-5. doi: 10.1002/ajh.23273.

5.

Polymorphisms in immune function genes and non-Hodgkin lymphoma survival.

Aschebrook-Kilfoy B, Zheng T, Foss F, Ma S, Han X, Lan Q, Holford T, Chen Y, Leaderer B, Rothman N, Zhang Y.

J Cancer Surviv. 2012 Mar;6(1):102-14. doi: 10.1007/s11764-010-0164-4.

6.

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.

Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, Pott C, Kopp N, Murakami M, Horn H, Leich E, Moccia AA, Mottok A, Sunkavalli A, Van Hummelen P, Ducar M, Ennishi D, Shulha HP, Hother C, Connors JM, Sehn LH, Dreyling M, Neuberg D, Möller P, Feller AC, Hansmann ML, Stein H, Rosenwald A, Ott G, Klapper W, Unterhalt M, Hiddemann W, Gascoyne RD, Weinstock DM, Weigert O.

Lancet Oncol. 2015 Sep;16(9):1111-22. doi: 10.1016/S1470-2045(15)00169-2.

PMID:
26256760
7.

Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma.

Richendollar BG, Pohlman B, Elson P, Hsi ED.

Hum Pathol. 2011 Apr;42(4):552-7. doi: 10.1016/j.humpath.2010.08.015.

PMID:
21237493
8.

Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.

Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP, LeBlanc M, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Connors JM, Lansdorp PM, Ouyang Q, Lister TA, Davies AJ, Norton AJ, Muller-Hermelink HK, Ott G, Campo E, Montserrat E, Wilson WH, Jaffe ES, Simon R, Yang L, Powell J, Zhao H, Goldschmidt N, Chiorazzi M, Staudt LM.

N Engl J Med. 2004 Nov 18;351(21):2159-69.

9.
10.

Genetic polymorphisms in the metabolic pathway and non-Hodgkin lymphoma survival.

Han X, Zheng T, Foss FM, Lan Q, Holford TR, Rothman N, Ma S, Zhang Y.

Am J Hematol. 2010 Jan;85(1):51-6. doi: 10.1002/ajh.21580.

11.

Polymorphisms in DNA repair and one-carbon metabolism genes and overall survival in diffuse large B-cell lymphoma and follicular lymphoma.

Wang SS, Maurer MJ, Morton LM, Habermann TM, Davis S, Cozen W, Lynch CF, Severson RK, Rothman N, Chanock SJ, Hartge P, Cerhan JR.

Leukemia. 2009 Mar;23(3):596-602. doi: 10.1038/leu.2008.240. No abstract available.

12.

Inherited genetic variation and overall survival following follicular lymphoma.

Gibson TM, Wang SS, Cerhan JR, Maurer MJ, Hartge P, Habermann TM, Davis S, Cozen W, Lynch CF, Severson RK, Rothman N, Chanock SJ, Morton LM.

Am J Hematol. 2012 Jul;87(7):724-6. doi: 10.1002/ajh.23184.

13.

Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project.

Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, Pro B, Pileri S, Pulsoni A, Soubeyran P, Cortelazzo S, Martinelli G, Martelli M, Rigacci L, Arcaini L, Di Raimondo F, Merli F, Sabattini E, McLaughlin P, Solal-Céligny P.

J Clin Oncol. 2009 Sep 20;27(27):4555-62. doi: 10.1200/JCO.2008.21.3991.

PMID:
19652063
14.

Inactivation of the CDKN2A tumor-suppressor gene by deletion or methylation is common at diagnosis in follicular lymphoma and associated with poor clinical outcome.

Alhejaily A, Day AG, Feilotter HE, Baetz T, Lebrun DP.

Clin Cancer Res. 2014 Mar 15;20(6):1676-86. doi: 10.1158/1078-0432.CCR-13-2175.

15.

Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL).

Farinha P, Masoudi H, Skinnider BF, Shumansky K, Spinelli JJ, Gill K, Klasa R, Voss N, Connors JM, Gascoyne RD.

Blood. 2005 Sep 15;106(6):2169-74.

16.

Prognostic factors in follicular lymphoma: a single institution study.

Jacobi N, Rogers TB, Peterson BA.

Oncol Rep. 2008 Jul;20(1):185-93.

PMID:
18575736
18.

Association between genetic variations in tumor necrosis factor receptor genes and survival of patients with T-cell lymphoma.

Zhai K, Chang J, Wu C, Lu N, Huang LM, Zhang TW, Yu DK, Tan W, Lin DX.

Chin J Cancer. 2012 Jul;31(7):335-41. doi: 10.5732/cjc.011.10448.

19.

The prognostic value of mid- and post-treatment [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in indolent follicular lymphoma.

Lu Z, Lin M, Downe P, Chong S, Ling S.

Ann Nucl Med. 2014 Oct;28(8):805-11. doi: 10.1007/s12149-014-0874-1.

PMID:
25008291
20.

Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms.

Ghesquières H, Cartron G, Seymour JF, Delfau-Larue MH, Offner F, Soubeyran P, Perrot A, Brice P, Bouabdallah R, Sonet A, Dupuis J, Casasnovas O, Catalano JV, Delmer A, Jardin F, Verney A, Dartigues P, Salles G.

Blood. 2012 Sep 27;120(13):2650-7.

Supplemental Content

Support Center